Tianasen for GNAO1-related epilepsy and movement disorders
Part of Brain & nervous system clinical trials.
This trial tests a new drug called Tianasen for children with a specific GNAO1 gene change who have seizures and movement problems that haven't improved with standard treatments. The drug is given via a lumbar puncture (spinal tap) and aims to reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 14 years old
- A genetic test must show the specific c.607G>A change in the GNAO1 gene
- Your child must have both epilepsy and movement disorders (like dystonia or hyperkinesias) that haven't improved after trying at least two standard medications
- For girls who have started menstruating, a pregnancy test must be negative and effective birth control must be used during the study
- Your child cannot have any other medical condition or infection that would make a spinal tap unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for children with Timothy syndrome, a rare genetic condition that can cause heart, developmental, and brain problems. It aims to see if the drug can prevent or ease symptoms like seizures, autism, and developmental delays when started early.
This study tests a new treatment called ASO (antisense oligonucleotide) therapy on tissue samples from babies with syndromic craniosynostosis—a condition where skull bones fuse too early due to specific genetic changes. Researchers hope this approach could eventually help prevent or reduce the severity of this condition.
This trial tests a single patient's response to an experimental genetic treatment (called an ASO) for a rare brain disease caused by changes in the TUBB4A gene. The goal is to see if the treatment can improve symptoms related to the condition H-ABC.
This trial tests a new genetic medicine designed for people with A-T who have a specific ATM gene change. It aims to see if the treatment is safe and if it can improve symptoms.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
This is a follow-up study for patients who previously received an experimental gene therapy (scAAV9/JeT-GAN) for giant axonal neuropathy (GAN), a rare genetic nerve disorder. The new treatment delivers the therapy directly into the vagus nerve—a major nerve in the neck—to help manage nerve damage and related symptoms.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.